Skip to Content
Merck
All Photos(1)

Documents

P4099900

Pyridostigmine bromide

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

3-(Dimethylaminocarbonyloxy)-1-methylpyridinium bromide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H13BrN2O2
CAS Number:
101-26-8
Molecular Weight:
261.12
MDL number:
MFCD00079283
UNSPSC Code:
41116107
PubChem Substance ID:
329820197
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

pyridostigmine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[Br-].CN(C)C(=O)Oc1ccc[n+](C)c1

InChI

1S/C9H13N2O2.BrH/c1-10(2)9(12)13-8-5-4-6-11(3)7-8;/h4-7H,1-3H3;1H/q+1;/p-1

InChI key

VNYBTNPBYXSMOO-UHFFFAOYSA-M

Gene Information

human ... ACHE(43)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Pyridostigmine bromide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Acetylcholinesterase inhibitor.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H300 + H310 + H330,H317

Hazard Classifications

Acute Tox. 1 Inhalation - Acute Tox. 2 Dermal - Acute Tox. 2 Oral - Skin Sens. 1

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

João Paulo J Sabino et al.
Autonomic neuroscience : basic & clinical, 173(1-2), 58-64 (2012-12-12)
Sympathetic hyperactivity and its outcome in heart failure have been thoroughly investigated to determine the focus of pharmacologic approaches targeting the sympathetic nervous system in the treatment of this pathophysiological condition. On the other hand, therapeutic approaches aiming to protect
Marcus Paulo Ribeiro Machado et al.
Experimental physiology, 97(11), 1186-1202 (2012-06-19)
The aim of the present study was to evaluate the effects of changes to the autonomic nervous system in mice during the acute phase of Chagas disease, which is an infection caused by the parasite Trypanosoma cruzi. The following types
Renata M Lataro et al.
American journal of physiology. Regulatory, integrative and comparative physiology, 305(8), R908-R916 (2013-08-21)
Heart failure (HF) is characterized by elevated sympathetic activity and reduced parasympathetic control of the heart. Experimental evidence suggests that the increase in parasympathetic function can be a therapeutic alternative to slow HF evolution. The parasympathetic neurotransmission can be improved
H Zach et al.
European journal of neurology, 20(4), 708-713 (2013-01-03)
Several small retrospective studies have observed that patients with a purely ocular manifestation of myasthenia gravis (MG) are significantly less likely to convert to a generalized disease when treated early on with corticosteroids. However, given the limited number of reported
Marloes J A Joosen et al.
Chemico-biological interactions, 203(1), 149-153 (2012-10-23)
Low volatile organophosphorous nerve agents such as VX, will most likely enter the body via the skin. The pharmacokinetics of drugs such as oximes, atropine and diazepam, are not aligned with the variable and persistent toxicokinetics of the agent. Repeated
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service